Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (2): 206-208.DOI: 10.3969/j.issn.1673-8640.2021.02.018
Previous Articles Next Articles
Received:2020-04-01
Online:2021-02-28
Published:2021-02-28
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.02.018
| 组别 | 例数 | 性别 | 年龄/岁 | 基础疾病 | 就诊间隔时长/d | ||
|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | 例数 | 百分比% | ||||
| 普通型组 | 24 | 14 | 10 | 43.08±17.73 | 5 | 20.8 | 6.15±5.93 |
| 重型组 | 29 | 14 | 15 | 62.14±16.53 | 27 | 93.1 | 15.21±7.31 |
| 统计值 | 0.533 | -4.043 | 28.670 | -4.886 | |||
| P值 | 0.465 | <0.001 | <0.001 | <0.001 | |||
| 组别 | 例数 | 性别 | 年龄/岁 | 基础疾病 | 就诊间隔时长/d | ||
|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | 例数 | 百分比% | ||||
| 普通型组 | 24 | 14 | 10 | 43.08±17.73 | 5 | 20.8 | 6.15±5.93 |
| 重型组 | 29 | 14 | 15 | 62.14±16.53 | 27 | 93.1 | 15.21±7.31 |
| 统计值 | 0.533 | -4.043 | 28.670 | -4.886 | |||
| P值 | 0.465 | <0.001 | <0.001 | <0.001 | |||
| 组别 | 例数 | WBC计数/（×109/L） | NEUT#/（×109/L） | NEUT%/% | LYMPH#/（×109/L） | LYMPH%/% | CD3+%/% | CD3+细胞计数/ （个/μL） | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 普通型组 | 24 | 4.09±1.67 | 2.47±1.53 | 57.45±13.16 | 1.19±0.47 | 31.48±11.37 | 67.41±10.04 | 729.38±371.37 | |||||||
| 重型组 | 29 | 8.33±5.28 | 6.57±5.21 | 72.46±14.89 | 1.15±0.53 | 18.61±12.49 | 68.03±13.51 | 697.45±456.69 | |||||||
| 统计值 | -4.081 | -4.043 | -3.850 | 0.317 | 3.886 | -0.186 | -2.729 | ||||||||
| P值 | <0.001 | <0.001 | <0.001 | 0.752 | <0.001 | 0.853 | 0.009 | ||||||||
| 组别 | CD4+%/% | CD4+细胞计数/（个/μL） | CD4+/CD8+比值 | 淋巴细胞总数/（个/μL） | CRP/（mg/L） | LDH/（U/L） | |||||||||
| 普通型组 | 35.71±7.57 | 377.67±177.73 | 1.35±0.54 | 1 063.75±529.22 | 12.20（3.2~41.05） | 201.88±58.41 | |||||||||
| 重型组 | 44.07±14.23 | 450.43±308.50 | 2.40±1.48 | 1 017.43±647.12 | 27.90（8.43~70.95） | 298.86±149.54 | |||||||||
| 统计值 | 0.275 | -1.073 | -3.533 | 0.281 | 3.290 | -3.209 | |||||||||
| P值 | 0.784 | 0.289 | 0.001 | 0.780 | 0.070 | 0.003 | |||||||||
| 组别 | 例数 | WBC计数/（×109/L） | NEUT#/（×109/L） | NEUT%/% | LYMPH#/（×109/L） | LYMPH%/% | CD3+%/% | CD3+细胞计数/ （个/μL） | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 普通型组 | 24 | 4.09±1.67 | 2.47±1.53 | 57.45±13.16 | 1.19±0.47 | 31.48±11.37 | 67.41±10.04 | 729.38±371.37 | |||||||
| 重型组 | 29 | 8.33±5.28 | 6.57±5.21 | 72.46±14.89 | 1.15±0.53 | 18.61±12.49 | 68.03±13.51 | 697.45±456.69 | |||||||
| 统计值 | -4.081 | -4.043 | -3.850 | 0.317 | 3.886 | -0.186 | -2.729 | ||||||||
| P值 | <0.001 | <0.001 | <0.001 | 0.752 | <0.001 | 0.853 | 0.009 | ||||||||
| 组别 | CD4+%/% | CD4+细胞计数/（个/μL） | CD4+/CD8+比值 | 淋巴细胞总数/（个/μL） | CRP/（mg/L） | LDH/（U/L） | |||||||||
| 普通型组 | 35.71±7.57 | 377.67±177.73 | 1.35±0.54 | 1 063.75±529.22 | 12.20（3.2~41.05） | 201.88±58.41 | |||||||||
| 重型组 | 44.07±14.23 | 450.43±308.50 | 2.40±1.48 | 1 017.43±647.12 | 27.90（8.43~70.95） | 298.86±149.54 | |||||||||
| 统计值 | 0.275 | -1.073 | -3.533 | 0.281 | 3.290 | -3.209 | |||||||||
| P值 | 0.784 | 0.289 | 0.001 | 0.780 | 0.070 | 0.003 | |||||||||
| 项目 | B值 | 标准误 | Wald值 | P值 | HR值（95%CI） |
|---|---|---|---|---|---|
| 基础疾病 | 4.76 | 1.62 | 8.59 | 0.003 | 116.47（4.83~2 805.89） |
| 就诊间隔时长 | 0.21 | 0.09 | 5.71 | 0.017 | 1.24（1.04~1.48） |
| 淋巴细胞总数 | 3.40 | 1.40 | 5.86 | 0.015 | 29.83（1.91~466.20） |
| 项目 | B值 | 标准误 | Wald值 | P值 | HR值（95%CI） |
|---|---|---|---|---|---|
| 基础疾病 | 4.76 | 1.62 | 8.59 | 0.003 | 116.47（4.83~2 805.89） |
| 就诊间隔时长 | 0.21 | 0.09 | 5.71 | 0.017 | 1.24（1.04~1.48） |
| 淋巴细胞总数 | 3.40 | 1.40 | 5.86 | 0.015 | 29.83（1.91~466.20） |
| [1] | 国家卫生健康委办公厅. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL].(2020-3-30) [2020-03-30]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtm. |
| [2] | XU X,CHEN P,WANG J,et al.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J/OL]. Sci China Life Sci,2020,63(3):457-460. |
| [3] | ZHENG M,GAO Y,WANG G,et al.Functional exhaustion of antiviral lymphocytes in COVID-19 patients[J]. Cell Mol Immunol,2020,7(5):533-535. |
| [4] | 胡家光,蒋忠胜,李旭,等. 新型冠状病毒肺炎患者16例外周血T淋巴细胞亚群的变化及意义[J]. 广东医学,2020,41(8):781-783. |
| [5] | HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet,2020,395:497-506. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
